目的探讨紫杉醇联合顺铂治疗晚期乳腺癌患者的临床疗效并分析。方法 24例患者均采用紫杉醇联合顺铂进行治疗,均为复发转移性乳腺癌,其中紫杉醇采用静脉滴注在患者开始治疗的d1,剂量为135mg/(m2·d),d1-d3给予患者静脉滴入顺铂,剂量为25mg/(m2·d)静脉滴入。21d为1个周期进行治疗,患者治疗2个周期后进行疗效评价。结果在本次研究的24例患者中,均治疗2个周期,可进行疗效评价,其中有2例患者经治疗后其病情得到完全缓解,有11例患者的病情得到部分缓解,总治疗效果为54.17%;中位肿瘤进展时间为5.5个月,一年内患者的生存率为50.0%,中位的生存期为18.6个月;患者经治疗后的主要毒性反应为骨髓抑制和严重的胃肠道反应。结论采用紫杉醇联合顺铂治疗晚期乳腺癌患者取得较好的治疗效果,且患者用药后可耐受其药物带来的毒副反应。 Objective To investigate the clinical efficacy of paclitaxel combined with cisplatin in the treatment of patients with advanced breast cancer. Methods Twenty-four patients were treated with paclitaxel combined with cisplatin, all of whom had recurrent metastatic breast cancer. Paclitaxel was intravenously administered to patients at the d1 dose of 135 mg / (m2 · d), and d1-d3 was given intravenously Drip cisplatin, a dose of 25mg / (m2 · d) intravenous infusion. 21d for a cycle of treatment, treatment of patients after 2 cycles of efficacy evaluation. Results 24 patients in this study were treated for 2 cycles, the efficacy evaluation, of which 2 patients after treatment, the disease was completely relieved, and 11 patients were partially relieved of the disease, the total treatment effect was 54.17%. The median time to tumor progression was 5.5 months. The one-year survival rate was 50.0% and the median survival time was 18.6 months. The major toxicities after treatment were myelosuppression and severe gastrointestinal reaction. Conclusion Paclitaxel combined with cisplatin in patients with advanced breast cancer achieved better therapeutic effect, and patients can tolerate the drug’s side effects.